Comparison of Diagnosis-Based Risk Adjustment Models for Episode-Based Cost
Author(s)
Kim J1, Ock M2, Oh IH3, Jo MW1, Kim Y4, Lee MS1, Lee SI1
1University of Ulsan College of Medicine, Seoul, Korea, Republic of (South), 2Ulsan University Hospital, University of Ulsan College of Medicine, ULSAN, Korea, Republic of (South), 3Kyung Hee University, Seoul, Korea, Republic of (South), 4Seoul National University, Seoul, Korea, Republic of (South)
Presentation Documents
OBJECTIVES: This study aims to compare the performance of diagnosis-based risk adjustment methods based on the episode-based cost to utilize in episode-based efficiency measurement.
METHODS: We used the health insurance claims data from South Korea, the Health Insurance Review and Assessment Service – National Patient Sample (HIRA-NPS). A separate linear regression model was constructed using 2018 HIRA-NPS, depending on the Major Diagnostic Category (MDC). Individual models included explanatory (demographics, types of insurance, institutional types, diagnosis-based risk adjustment methods) and response variables (episode-based costs). The model’s risk adjustment methods were as follows: Refined Diagnosis Related Group (RDRG), Charlson Comorbidity Index (CCI), National Health Insurance Service Hierarchical Condition Categories (NHIS-HCC), and Department of Health and Human Service-HCC (HHS-HCC). The accuracy of models was compared using R-squared (R2), Mean Absolute Error (MAE), and Predictive Ratio (PR). External validity was evaluated using HIRA-NPS in 2017.
RESULTS: The model including RDRG improved mean R2 from 34.2% to 38.5% compared to the adjacent DRG. However, RDRG was inferior to both HCCs (RDRG, 38.5%; NHIS-HCC, 40.6%; HHS-HCC, 41.4%), though it was superior to CCI. We observed the variability of model performance depending on MDC groups. While both HCCs had the highest explanatory power in 11 MDCs, including MDC P (Newborns), RDRG showed the highest adjusted R2 in 6 MDCs, such as MDC O (Pregnancy, childbirth, and puerperium). The average MAEs were the lowest in the model with RDRG (KRW 1,297,000). The PRs showed similar patterns between models in the following subgroups: age, sex, institutional types, types of insurance, and upper and lower ten percentile of actual costs. External validity also showed a similar pattern in the model performance.
CONCLUSIONS: This research showed the applicability of both HCCs to adjust comorbidities, excluding complications, for episode-based costs in the process of efficiency measurement.
Conference/Value in Health Info
Value in Health, Volume 25, Issue 12S (December 2022)
Code
HPR130
Topic
Health Policy & Regulatory
Topic Subcategory
Public Spending & National Health Expenditures, Risk-sharing Approaches
Disease
No Additional Disease & Conditions/Specialized Treatment Areas